Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.

Affiliations

¹ Department of Clinical Therapeutics, School of Medicine, and.
² Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece; and.
³ Department of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, Athens, Greece.

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Aging / immunology
Antibodies, Neutralizing / biosynthesis*
Antibodies, Neutralizing / immunology
Antibodies, Viral / biosynthesis*
Antibodies, Viral / immunology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
BNT162 Vaccine
COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / immunology*
Clinical Trials as Topic / statistics & numerical data
Female
Humans
Immunocompromised Host
Immunogenicity, Vaccine / immunology*
Male
Middle Aged
Multiple Myeloma / drug therapy
Multiple Myeloma / immunology*
Prospective Studies
SARS-CoV-2 / immunology*

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
BNT162 Vaccine